A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC)

NCT04606771 PHASE2 ACTIVE_NOT_RECRUITING Results posted

This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.

Details

Lead sponsor	AstraZeneca
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	30
Start date	Mon Sep 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Osimertinib + Savolitinib
• Savolitinib + Placebo

Countries

Taiwan, Vietnam, Argentina, Thailand, United States, India